6% CONVERTIBLE NOTE6% Convertible Note • February 14th, 2017 • Adgero Biopharmaceuticals Holdings, Inc. • Pharmaceutical preparations • New York
Contract Type FiledFebruary 14th, 2017 Company Industry JurisdictionTHIS AMENDMENT NO. 1 TO 6% CONVERTIBLE NOTE, dated as of March 25, 2016 (this “Amendment”), between Adgero Biopharmaceuticals, Inc., a Delaware corporation (the “Company”) and Robert F. Hendrickson (the “Investor”).
6% CONVERTIBLE NOTE6% Convertible Note • February 14th, 2017 • Adgero Biopharmaceuticals Holdings, Inc. • Pharmaceutical preparations • New York
Contract Type FiledFebruary 14th, 2017 Company Industry JurisdictionTHIS AMENDMENT NO. 1 TO 6% CONVERTIBLE NOTE, dated as of March 21, 2016 (this “Amendment”), between Adgero Biopharmaceuticals, Inc., a Delaware corporation (the “Company”) and Adam K. Stern (the “Investor”).
6% CONVERTIBLE NOTE6% Convertible Note • November 3rd, 2016 • Adgero Biopharmaceuticals Holdings, Inc. • Pharmaceutical preparations • New York
Contract Type FiledNovember 3rd, 2016 Company Industry JurisdictionTHIS AMENDMENT NO. 1 TO 6% CONVERTIBLE NOTE, dated as of March 28, 2016 (this “Amendment”), between Adgero Biopharmaceuticals, Inc., a Delaware corporation (the “Company”) and Dr. Roman Perez Soler (the “Investor”).